TP53 and B-cell chronic lymphocytic leukemia: AMPLIFY, the first phase 3 randomized clinical trial, compared the efficacy and safety of acalabrutinib and venetoclax combination with and without obinutuzumab in fixed-duration therapy versus standard-of-care chemoimmunotherapy in previously untreated adult CLL patients without del(17p) and/or TP53 mutations.